Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases. Co.'s Specialized BioTherapeutics business segment is developing a photodynamic therapy (SGX301) for the treatment of cutaneous T-cell lymphoma, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders. Co.'s Public Health Solutions business segment includes development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and other infectious disease. The SNGX stock yearly return is shown above.
The yearly return on the SNGX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SNGX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|